Dr. Mohamed M. Sayed-Ahmed is Professor of Pharmacology and Experimental Oncology, National Cancer Institute, Cairo University. He has graduated from College of Pharmacy in 1985. Two years later, he joined the National Cancer Institute, Cairo University, Egypt and completed his master thesis on the effect of local hyperthermia and some anticancer drugs on the treatment of Solid Ehrlich Carcinoma in 1992. Dr. Sayed-Ahmed went to USA, in 1994, to perform the experimental part of his Ph.D thesis at the College of Medicine, Duke University Medical Centre, Durham, North Carolina. There, he spent three years investigating the mechanisms by which Doxorubicin induces its cardiomyopathy and how Doxorubicin interferes with our carnitine system in the heart and how carnitine supplementation prevents doxorubicin-induced cardiac metabolic damage. In 2004, he joined the Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Saudi Arabia as one of the university staff and research group member. There, King Saud University granted him several research projects to pursue his research in Carnitine and cancer Chemotherapy-induced cardiomyopathy. In King Saud University, Dr. Sayed-Ahmed supervised FOUR M.Sc and TWO Ph.D Thesis and acted as main Examiner for more than 20 master and Ph.D. thesis. In 2017, Dr. Sayed-Ahmed returned back home Egypt as full professor of Pharmacology and Experimental Oncology, National Cancer Institute, Cairo University. Dr. Sayed-Ahmed published more than 83 articles and acted as Editorial Board Member and Peer Reviewer for many international Journals. In 2019, Dr. Sayed-Ahmed has been selected by supreme council of universities as an active member in the committee for promoting associate and professors in both pharmacology and clinical pharmacy. In the last three successive years (2020, 2021 and 2022), Dr. Sayed-Ahmed has been recognized among the top 2 % of scientists in the World according to Stanford University.